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Protein kinase C (PKC) is a family of serine/threonine kinases
that play isoform-specific inhibitory and stimulatory roles in
platelet activation. We show here that the pan-PKC inhibitor
Ro31-8220 can be used to dissect these events following platelet
activation by ADP. Submaximal concentrations of Ro31-8220
potentiated aggregation and dense granule secretion to ADP in
plasma anticoagulated with citrate, in D-Phe-Pro-Arg-chloro-
methyl ketone-anticoagulated plasma, which has physiological
levels of Ca2, and in washed platelets. Potentiation was
retained on inhibition of cyclooxygenase and was associated
with an increase in intracellular Ca2. Potentiation of aggrega-
tion and secretion was abolished by a maximally effective con-
centration of Ro31-8220, consistent with a critical role of PKC
in secretion. ADP-induced secretion was potentiated in the
presence of an inhibitor of PKC but not in the presence of
available inhibitors of other PKC isoforms in human andmouse
platelets. ADP-induced secretion was also potentiated inmouse
platelets deficient in PKC but not PKC. These results demon-
strate that partial blockade of PKC potentiates aggregation and
dense granule secretion by ADP in association with increased
Ca2. This provides a molecular explanation for the inability of
ADP to induce secretion in plasma in the presence of physiolog-
ical Ca2 concentrations, and it reveals a novel role for PKC in
inhibiting platelet activation by ADP in vivo. These results also
demonstrate isoform-specific inhibitory effects of PKC in
platelets.
Platelets play a vital role in the generation of a thrombus or
vascular plug, preventing excessive blood loss following vascu-
lar injury. Circulating platelets adhere rapidly to exposed sub-
endothelial matrix proteins and undergo activation leading to
granule secretion, thromboxane A2 (TxA2)6 formation, and
integrin activation. This is followed by aggregation of platelets
by binding of fibrinogen to activated integrin IIb3. The con-
version of fibrinogen to fibrin and platelet contraction consol-
idates the growing thrombus (1, 2). Aggregate growth is deter-
mined by a synergy between the two feedback mediators, ADP,
which is released fromdense granules, andTxA2,which ismade
de novo from liberated arachidonic acid.
ADP is a weak platelet agonist in comparison with other G
protein-coupled receptor agonists such as thrombin. ADP is
released from platelets following endothelial cell damage, in
response to all stimulatory platelet agonists, and acts as a sec-
ondary positive feedback mediator of platelet activation (3, 4).
ADP signals through twoGprotein-coupled receptors. TheGq-
coupled P2Y1 receptor activates phospholipase C isoforms
leading to formation of the second messengers 1,2-diacylglyc-
erol and inositol 1,4,5-trisphosphate, which activate protein
kinase C (PKC) and mobilize Ca2, respectively. The Gi-cou-
pled P2Y12 receptor inhibits adenylyl cyclase and activates PI
3-kinase (5, 6). The latter is believed to underlie the ability of
P2Y12 to synergize with other Ca2-mobilizing receptors,
includingGq- and tyrosine kinase receptor-regulated pathways,
such as the P2Y1 receptor (7, 8), theTxA2 receptor, and integrin
IIb3 (9, 10).
Paradoxically, it has been observed that ADP is able to stim-
ulate sustained aggregation and marked dense granule secre-
tion in citrated plasma that containsmicromolar levels of Ca2,
whereas it induces only transient aggregation and is unable to
stimulate dense granule secretion in the presence of physiolog-
ical andmillimolar concentrations of the cation. This difference
has been shown to be associated with increased TxA2 synthesis
(11) in citrated plasma suggesting that extracellularCa2 inhib-
its ADP-induced TxA2 formation (9) (12, 13). However, the
molecular basis of this paradox is unknown.
PKC is a family of closely related serine/threonine kinases,
composed of multiple isoforms that are subdivided into classi-
cal (, I, II, and ), novel (, , , and ) and atypical ( and
	/
) families, according to their sensitivity to 1,2-diacylglycerol
and Ca2 (14). The classical isoforms are regulated by 1,2-dia-
cylglycerol and Ca2; the novel isoforms are regulated by 1,2-
diacylglycerol, and the atypical isoform is not regulated by
eithermessenger. Robust expression of several isoforms of PKC
has been reported in human (, , , and ) and mouse (, , ,
, and ) platelets with evidence of expression of additional
isoforms (15–18). Studies using pan-PKC inhibitors have
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shown that the PKC superfamily plays a critical, positive role in
platelet aggregation to thrombin, although its role downstream
of the positive feedback agonist ADP is less well characterized
(19–24). Several members of the PKC superfamily are impli-
cated in activation of integrin IIb3 and in dense granule
release. For example, PKC has been shown, in both human
and mouse platelets, to play positive roles in the regulation of
both  and dense granule secretion (25, 26) and platelet aggre-
gation (27) downstream of several platelet agonists (28). PKC,
another classical isoform, has been shown to positively regulate
outside-in signaling by integrin IIb3 in mouse platelets (29).
However, studies investigating individual aspects of platelet
signaling pathways have shown that PKC can also function to
negatively feedback and limit platelet activation (30–34).
Although studies using mice deficient in various isoforms have
identified a positive role for PKC in GPVI signaling (18), both
positive and negative roles for PKC and PKC have been
described in supporting platelet activation downstream of
thrombin and collagen, thus demonstrating that the role of
PKC is isotype-dependent (35–38).
As yet, no role for PKC in inhibiting responses induced by
ADP has been reported. We have investigated the role of the
PKC superfamily downstream of ADP-induced platelet activa-
tion in human platelets. Using a range of concentrations of the
pan-PKC inhibitor Ro31-8220, we attempted to distinguish
between the stimulatory and inhibitory actions of the PKC
superfamily in human platelets. We observe a marked potenti-
ation in dense granule secretion and aggregation to ADP in
citrated platelet-rich plasma (PRP) by a submaximal but not
maximal concentration of the PKC inhibitor. Potentiation is
also observed in PRP in the presence of millimolar concentra-
tions of extracellular Ca2 and in ADP-sensitive washed plate-
lets. These results highlight the level of PKC activity as a key
regulator of platelet secretion by ADP in plasma, suggesting
that the inability of ADP to stimulate secretion in the presence
of physiological Ca2 is due to PKC activity. Mouse platelets
deficient in the novel isoformPKC show increased dense gran-
ule secretion in response to ADP, demonstrating a role for the
novel isoform in the inhibitory effect of PKC downstream of
ADP inmouse platelets. In addition, isoform-specific inhibitors
of PKC indicate a role for the classical isoform PKC in the
inhibitory effect of PKC downstream of ADP in human and
mouse platelets.
EXPERIMENTAL PROCEDURES
PKC-deficientmice (39) were bred as heterozygotes on a B6
background, and all results were compared with wild type lit-
ter-matched controls. D-Phe-Pro-Arg-chloromethyl ketone,
HCl, PKC inhibitor (3(-(1-(3-imidazol-1-ylpropyl)-1H-indol-
3-yl)-4-anilino-1H-pyrrole-2,5-dione), and rottlerin were from
Merck. Fura-2-AMwas a product of Invitrogen. Anti-phospho-
serine (PKC) substratemonoclonal antibody was fromCell Sig-
naling Technology (Beverly, MA). Anti-mouse HRP-conju-
gated antibody was from Dako. Ro31-8220, Ro31-8425,
Go¨6983, and other reagents were from Sigma.
Human andMouse Platelet Preparation—Studies on human
platelets were carried out with ethical approval from the
Oxford Research Ethic Council (reference number 08/H0605/
123). Blood was drawn from aspirin-free, healthy consenting
volunteers. For citrated PRP, whole blood was drawn into one-
tenth total volume of sodium citrate. For plasma containing
extracellular calcium, blood was collected into 60 M D-Phe-
Pro-Arg-chloromethyl ketone. For ADP-sensitive washed
platelets, blood was taken into one-sixth total volume of acid
citrate dextrose. PRP and washed platelets were prepared as
described previously (18). Platelets were resuspended in modi-
fied Tyrode’s HEPES buffer containing apyrase to prevent ADP
receptor desensitization (138 mM NaCl, 2.7 mM KCl, 1 mM
MgCl2, 3 mMNaH2PO4, 5 mM glucose, 10 mMHEPES, and 0.05
unit/ml apyrase), pH 7.3, adjusted to a concentration of 2 108
platelets/ml, and left to rest for 1 h at 37 °C. Animals were bred,
and blood was removed under an approved Home Office
License (reference number PPL 30/2721). Blood was drawn
either by cardiac puncture or from the vena cavae of terminally
CO2-narcosed mice, anesthetized with gaseous isofluorane.
Bloodwas taken into 100l of sodiumcitrate and centrifuged at
200  g for 6 min to obtain PRP. Platelets were counted to
ensure a platelet count of at least 108 platelets/ml.
Aggregometry and ATP Release—Aggregation and ATP
secretionweremonitored as described previously (18). Platelets
were preincubated for 3 min in the presence or absence of
Ro31-8220, Ro31-8425, Go¨6983, PKC inhibitor, Cangrelor/
ARC-6699331MX, MRS-2179, indomethacin, or PMA before
stimulation with agonist. Each sample was allowed to aggregate
for at least 2.5 min. An ATP standard was added to calculate
secretion.
Measurement of Intracellular Calcium—Washed platelets
were incubated with 3 M Fura-2-AM for 1 h at 37 °C in the
presence or absence of Ro31-8220. ADP was added to platelet
suspension at 37 °Cunder continuous stirring (1200 rpm). Fluo-
rescence changes were monitored using a fluorimeter (340 nm
excitation and 510 nm emission). Changes in intracellular cal-
cium concentration were calculated using the Grynkiewicz
equation (40).
Western Blot Analysis—Washed platelets (5  108/ml) acti-
vated as described above were lysed and analyzed by Western
blot as described previously (18). Phosphoserine PKC substrate
proteins were detected by incubation overnight at 4 °C with a
monoclonal anti-phosphoserine PKC substrate antibody.
Statistical Analysis—Statistical analyses were carried on data
using unpaired, two-tailed Student’s t test, and p  0.05 was
considered statistically significant. Values are expressed as
mean S.E.
RESULTS
Submaximal Ro31-8220 Potentiates Aggregation and Secre-
tionDownstreamof ADPbutNot PAR-1 Peptide—Studies using
mutant mice have revealed isoform-specific inhibitory and
stimulatory effects of the PKC superfamily on platelet function
downstream of strong platelet agonists such as collagen and
thrombin (15, 18, 20, 25, 31, 35, 37, 41–47). In an attempt to
dissect this balancing role of PKC in human platelets, we mon-
itored the effect of a range of concentrations of the pan-PKC
inhibitor Ro31-8220 on platelet activation in PRP and washed
platelets.
PKC in ADP-induced Platelet Activation
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Many pharmacological reagents have reduced bioavailability
in plasma (31). Although 10 M Ro31-8220 is commonly used
for total inhibition of the PKC superfamily in washed platelets,
the concentration required to completely inhibit PKC in
plasma is not known. Therefore, the effect of different concen-
trations of Ro31-8220 on platelet aggregation and dense gran-
ule secretion was compared in PRP andwashed platelets down-
stream of stimulation of the G protein-coupled PAR-1 receptor
using the PAR-1 peptide TRAP, as both of these responses are
known to be PKC-dependent (Fig. 1). In washed platelets,
increasing concentrations of Ro31-8220 caused dose-depen-
dent inhibition of aggregation and dense granule secretion (Fig.
1A, panels i and ii). Although 1 M Ro31-220 was able to
achieve full inhibition of dense granule secretion in washed
platelets induced by TRAP, a 100-fold higher concentration
was required to achieve complete inhibition in PRP, and this
concentration was not sufficient to achieve the same level of
inhibition of aggregation as seen in washed platelets (Fig. 1B,
panels i and ii). This indicates that in PRP there is markedly
reduced bioavailability of Ro31-8220, most likely due to sub-
stantial protein binding, which effectively lowers its concentra-
tion by more than 2 orders of magnitude.
ADP, amajor feedback agonist in platelets, reinforces activa-
tion through the P2Y1 and P2Y12 receptors. Because the P2Y1
receptor undergoes marked desensitization upon exposure to
ADP, special conditions are required to maintain ADP-medi-
ated platelet activation in washed platelets. Therefore, platelet
activation by ADP is commonly monitored in citrated PRP,
which buffers extracellular Ca2. Under these conditions, high
ADP produces sustained aggregation and dense granule secre-
tion, although at lower concentrations ADP (3 M) stimulates
transient aggregation but not secretion (Fig. 2).
We tested the effect of near maximal and submaximal inhi-
bition of PKC on ADP-induced responses, starting in citrated
PRP. Ro31-8220 caused a minor reduction in aggregation to
100MADP in citrated PRP at concentrations of 10 and 100M
(Fig. 2A, panel i), which are submaximal and maximal, respec-
tively, as shown above inTRAP-stimulated platelets. Nearmax-
imal Ro31-8220 (100 M) completely inhibited dense granule
secretion to ADP. At a 10-fold lower concentration (10 M) of
Ro31-8220, the onset of secretionwas potentiated, although the
overall level of secretion was reduced (Fig. 2A, panel ii). The
same submaximal concentration of Ro31-8220 (10 M) also
converted the transient aggregation response to a low concen-
tration of ADP (3 M) in PRP to sustained aggregation in asso-
ciation with dense granule secretion (Fig. 2A, panels iii and iv).
This potentiation of the rate and extent of aggregation and
secretion was not observed downstream of low concentrations
of TRAP peptide (data not shown). These observations demon-
strate that partial blockade of PKC potentiates the rate of onset
and magnitude of secretion to ADP, which at a submaximal
concentration (3 M ADP) leads to sustained aggregation. At a
FIGURE1.Effect of Ro31-8220onaggregationanddensegranule secretionofhumanwashedplatelets and citratedPRP in response to stimulationby
PAR-1 peptide. Human washed platelets (A) and citrated PRP (B) were stimulated with 100 M TRAP (a PAR-1 peptide that stimulates the thrombin receptor
and is known to be active in both washed platelets and PRP) following incubation with increasing concentrations of Ro31-8220 (Ro). Panel i, aggregation was
measured by optical aggregometry. Panel ii, dense granule secretion was measured by monitoring ATP secretion using luminometry (n 3). * indicates p
0.05 in comparison with the DMSO-treated controls.
PKC in ADP-induced Platelet Activation
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higher concentration of ADP, the increase in rate of onset of
secretion associatedwith partial blockade of PKC is followed by
a diminished overall response, presumably due to a balance
between the inhibitory and stimulatory actions of PKC, asmax-
imal inhibition of PKC abolishes secretion.
ADP-induced aggregation and secretion in citrated plasma
have been attributed to an increase in TxA2 formation (9). In
confirmation of this, significant inhibition of dense granule
secretion to 100 M ADP is observed in the presence of the
cyclooxygenase inhibitor indomethacin in citrated plasma (Fig.
2C). Treatment with submaximal Ro31-8220 (10 M) in the
presence of indomethacin caused a partial restoration of this
secretion. These results confirm a critical role for TxA2 forma-
tion in mediating ADP-induced secretion but indicate the
potentiation induced by submaximal Ro31-8220 concentra-
tions is not dependent on TxA2 formation.
The physiological significance of this potentiation is unclear
because the studies were performed in plasma containing
micromolar concentrations of extracellular calcium, although
it should be noted that these conditions are commonly used for
platelet testing in the clinic. We therefore investigated the
effect of PKC inhibition in PRP containing physiological levels
of extracellular Ca2 where a maximally effective concentra-
tion of ADP (100 M) induces reversible aggregation and no
dense granule secretion (Fig. 3). In the presence of submaximal
Ro31-8220 (10 M), ADP (100 M) stimulates sustained aggre-
gation and dense granule secretion (Fig. 3), although the level of
secretionwasmuch lower than that observed in citrated plasma
FIGURE 2. Effect of Ro31-8220 (Ro) on aggregation and dense granule secretion of human citrated PRP in response to stimulation by ADP. Human
citrated PRP was stimulated with either maximal (100M) ADP (A, panels i and ii) or submaximal (3M) ADP (A, panels iii and iv). A, panels i and iii, aggregation
monitored by optical aggregometry. Panels ii and iv, dense granule secretion, monitored by ATP release. Representative traces of n  3. B, dense granule
secretion by PRP, monitored by ATP release to a range of ADP concentrations in the absence or presence of Ro31-8220 (10 M). C, effect of Ro31-8220 and
indomethacin ondensegranule secretionof humanPRP treatedwithorwithout (10M) Ro31-8220 and/or (10M) indomethacin, in response toADP. Platelets
were incubated with DMSO, Ro31-8220 (10 M), or indomethacin (10 M) for 3 min prior to ADP stimulation. n3. * indicates p 0.05 in comparison with
DMSO-treated controls. ** indicates p 0.05 in comparison with platelets treated with 10 M indomethacin and those treated with DMSO.
PKC in ADP-induced Platelet Activation
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(Fig. 2). In the presence of 100 M Ro31-8220, the aggregation
response to ADP was decreased and secretion abolished.
Therefore, submaximal inhibition of the PKC superfamily by
Ro31-8220 potentiates ADP-induced secretion in the presence
of physiological concentrations of Ca2. This raises the possi-
bility that inability of ADP to stimulate sustained aggregation
and secretion in Ca2-containing PRP is due to PKC exerting a
constitutive feedback effect and highlights the level of PKC
activity as a key regulator of platelet activation byADP in low or
normal Ca2 plasma.
Role of P2Y1 and P2Y12 in Potentiation of ADP Induced Plate-
let Activation—To address which of the two ADP receptors are
required for the potentiation by submaximal Ro31-8220,
human PRP was treated with either the P2Y1 inhibitor
MRS-2179 (MRS) or the P2Y12 inhibitor cangrelor/ARC-
6699331MX (ARC) and stimulated by a maximal (100 M) or
submaximal (3 M) ADP. Pretreatment with ARC blocked
dense granule secretion induced by ADP (100M) and reduced
aggregation to a diminished, transient response (Fig. 4A) (data
not shown). Significantly, neither response was rescued in the
presence of submaximal Ro31-8220 (10 M) (Fig. 4A) (data not
shown). Inhibition of the P2Y1 receptor using MRS (100 M)
(Fig. 4B) inhibited shape change, aggregation, and secretion to a
lower concentration of ADP (3 M). This inhibition, however,
could be rescued, and potentiation was observed in the pres-
ence of submaximal Ro31-8220, despite P2Y1 inhibition (Fig.
4B) (data not shown). This therefore indicates that potentiation
of aggregation is mediated by the P2Y12 receptor or the synergy
between P2Y1 and P2Y12.
Submaximal Inhibition of PKC Potentiates Aggregation,
Secretion, and Ca2 in Washed Platelets—We investigated
whether the potentiation following partial blockade of PKC
could be observed in washed platelets, using a lower range of
concentrations of Ro31-8220 to those in plasma, where it has
limited bioavailability (see Fig. 1). ADP (100 M) stimulated
weak, transient aggregation in washed platelets in the absence
of granule secretion (Fig. 5A). In the presence of submaximal
Ro31-8220 (0.3 and 1M), ADP (100M) stimulatedmaximally
sustained aggregation and dense granule secretion, with both
responses being inhibited in the presence of a maximally effec-
tive concentration of the PKC inhibitor (10 M) (Fig. 5A).
Potentiation is therefore not dependent on the presence of
plasma.
ADP-induced platelet activation is dependent on the mobi-
lization of intracellular Ca2 that plays a key role in mediating
aggregation and dense granule secretion (48, 49). It is known
that PKC has both inhibitory and stimulatory effects on Ca2
mobilization in platelets (15) so inhibition of the former could
underlie Ro31-8220-mediated potentiation. To address this,
washed plateletswere loadedwith theCa2 reporter dye Fura-2
(40) before stimulation by ADP. Ro31-8220 caused a concen-
tration-dependent increase in intracellular Ca2 induced by
ADP,with a threshold at 0.1Mand a peak effect at 1M,which
parallels the potentiation of aggregation and secretion (Fig. 5B).
The increase in Ca2 was sustained at a maximally effective
Ro31-8220 (10 M).
Potentiation IsWorking through PKC—One concernwas that
the effects of Ro31-8220 were due to an alternative target,
rather than thewell characterized inhibition of PKC, sowe used
a second pan-PKC inhibitor Ro31-8425 (45, 50). In washed
platelets, the presence of Ro31-8425 (0.3 and 1 M) stimulated
maximally sustained aggregation and dense granule secretion
to ADP (100M), whereas both responses were inhibited in the
presence of a maximally effective concentration of the pan-
PKC inhibitor (10 M) (supplemental Fig. 1). Furthermore,
ADP-stimulated Ca2 mobilization was potentiated over the
same concentration of Ro31-8425 (0.3–10 M). These results
are essentially the same as those with Ro31-8220.
We also investigated PKC-dependent substrate phosphory-
lation. As shown in Fig. 6A, Ro31-8220 inhibited phosphory-
lation of several PKC substrates in platelets downstream of
ADP and PMA, a direct activator of PKC (51), with the same
concentration-response relationships as seen for aggregation
on washed platelets. Weak inhibition of phosphorylation was
observed between 0.1 and 0.3MRo31-8220with full inhibition
at 10 M. The blot shows inhibition to all concentrations of
Ro31-8220 that have been usedmost likely due to the combined
inhibition ofmultiple isoforms. Thus, the potentiation of plate-
let activation by ADP by Ro31-8220 occurs over the same con-
centration range as those for inhibition of PKC-dependent
phosphorylation (Fig. 6).
We investigated whether activation of PKC using the phor-
bol ester PMA had the opposite effect on ADP-induced dense
FIGURE 3. Effect of Ro31-8820 on aggregation and dense granule secre-
tionofhumanPRP in thepresenceofextracellular calcium in response to
stimulation by ADP. Human PRP was prepared using D-Phe-Pro-Arg-chlo-
romethyl ketoneas ananticoagulant tomaintainphysiological levels of extra-
cellular calcium and incubated in the presence or absence of 10 or 100 M
Ro31-8220. Aggregation (A) and dense granule secretion (B) weremonitored
following stimulation by ADP (100 M). Traces are representative of n 3.
FIGURE 4. Effect of P2Y1 and P2Y12 inhibition on aggregation and dense
granule secretion of human citrated PRP in response to stimulation by
ADP in thepresenceandabsenceofRo31-8220.A,humancitratedPRPwas
stimulatedwithmaximal (100M) ADP in the absence or presence of ARC (10
M) and/or submaximal Ro31-8220 (Ro) (10 M). B, human citrated PRP was
stimulated with submaximal (3 M) ADP in the absence or presence of MRS
(100M) and/or submaximal Ro31-8220 (10M). Aggregationwasmonitored
by optical aggregometry. Traces are representative of n  3. Platelets were
incubatedwith DMSO, Ro31-8220 (10M), ARC (10M), orMRS (100M) for 3
min prior to ADP stimulation (n3).
PKC in ADP-induced Platelet Activation
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granule secretion. Pretreatment of platelets with increasing
concentrations of PMA led to a decrease in dense granule secre-
tion relative to control platelets following activation by ADP
(Fig. 6B). These results demonstrate that low level activation of
platelets by PMA mediates platelet inhibition in response to
ADP, consistent with a model in which antagonism of consti-
tutive signaling by the PKC superfamily underlies the potenti-
ation of ADP-induced aggregation and supporting the conclu-
sion that potentiation is a PKC-specific effect.
Role for the Novel PKC Isoform in the Regulation of ADP-
induced Platelet Activation in Mice—Our present results sug-
gest novel, opposing regulatory roles for members of the PKC
superfamily in platelet activation downstream of ADP, namely
an inhibitory role sensitive to low concentrations of Ro31-8220
and an activatory role sensitive to high concentrations of Ro31-
8220. There is increasing evidence that the novel isoforms of
the PKC superfamily have many negative roles in the processes
of platelet activation compared with the classical isoforms,
which have mainly positive roles (15, 18, 25, 27, 35–37, 41, 42,
44, 45). To determine whether one of the novel PKC isoforms
was responsible for potentiation, ADP-induced responses were
determined inmouse PRP. As for human platelets, submaximal
Ro31-8220 caused potentiation of dense granule secretion in
wild type (WT) mouse-citrated PRP (Fig. 7). We therefore
investigated ADP-induced responses in PRP frommice lacking
either the novel PKC isoforms PKC or PKC. Interestingly,
although no difference in aggregationwas observed in PRP har-
vested from PKC/mice following activation by a high con-
centration of 100 M ADP, dense granule secretion is potenti-
ated in PKC/ mice in comparison with WT controls to a
much greater extent than that seen with Ro31-8220. This
potentiation is reduced following treatment with Ro31-8220
indicating a positive role for PKC in ADP-induced platelet acti-
vation in mouse platelets. However, dense granule secretion is
not completely inhibited and can still be observed suggesting
involvement of an additional PKC isoform (Fig. 7). No signifi-
cant increase in ADP-induced secretion was observed in plate-
lets from PKC/mice (data not shown). These results dem-
onstrate that the potentiation observed in mouse platelets is
mediated, at least in part, through inhibition of PKC.
Role for the Classical Isoform PKC in the Regulation of ADP-
induced Platelet Activation in Human Platelets—Although
PKC clearly plays a role in mouse platelets, the lack of expres-
sion of PKC in human platelets points to the involvement of a
different isoform. Therefore, we tested the ability of inhibitors
of the PKC superfamily, which are reported to be selective to
various PKC isoforms, to show potentiation. These inhibitors
included Go¨6983 that primarily targets the classical PKC iso-
forms but also inhibits PKC, a PKC inhibitor (3-(1-(3-imid-
azol-1-yl-propyl)-1H-indol-3-yl)-4-anilino-1H-pyrrole-2,5-di-
one) that selectively inhibits the  isoform over PKC, - and
-, a PKC inhibitor (52), and rottlerin, which has been used as
a PKC inhibitor. The frequently used classical isoform inhibi-
FIGURE 5.Mechanisms of potentiation by submaximal concentrations of Ro31-8220 in human washed platelets. A, effect of Ro31-8220 (Ro) on aggre-
gation and dense granule secretion in response to stimulation by ADP. Human ADP-sensitive washed platelets were stimulated with 100 M ADP in the
presence and absence of varying concentrations of Ro31-8220 (0.1, 0.3, 1, and 10 M). Aggregation (panel i) and dense granule secretion (panel ii) were
monitored as describedpreviously. B, effect of Ro31-8220 on intracellular calcium levels followingADP stimulation. Humanwashedplateletswere loadedwith
Fura-2-AM and pretreatedwith or without varying concentrations of Ro31-8220 before stimulationwith 100M ADP. Fluorescencewasmeasured before and
after (1min) ADP addition, and the increase in intracellular calcium concentrationwas calculated using theGrynkiewicz equation. Platelets were incubated for
3 min with inhibitor(s) or DMSO prior to ADP stimulation. Representative traces are shown. Data are presented as mean S.E., n3. * indicates p 0.05 in
comparison with DMSO-treated controls.
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tor Go¨6976 has recently been found to inhibit the tyrosine
kinase Syk in human platelets, and so it was not used (53).
Potentiation of aggregation and secretion to ADP (100 M)
were observed in the presence of Go¨6983 and the PKC inhib-
itor (10 M) in human washed platelets (supplemental Fig. 2
andFig. 8). A concentration-dependent increase in intracellular
Ca2 by ADP was also observed in the presence of the PKC
inhibitor (0.3–10 M) (Fig. 8A, panel iii). In contrast, neither
the PKC inhibitor (0.1–30 M) nor rottlerin (0.3–30 M)
potentiated the response to ADP (data not shown). The PKC
inhibitor (10 and 30 M) also potentiated ADP-induced
responses in mouse PRP (Fig. 8B). Together, these results sup-
port a role for PKC in inhibiting activation by ADP in human
and mouse platelets.
DISCUSSION
The PKC superfamily is a key regulator of platelet activation
downstream of a range of platelet agonists, including ADP as
shown in this study. Studies of the individual isoforms of PKC
have highlighted both positive and negative regulatory roles for
the kinase in several processes required for platelet activation
and thrombus formation (15, 18–21, 23, 25–27, 30–32, 35–37,
42–45, 47, 50). In an attempt to differentiate the net effect of
the PKC superfamily on ADP activation, we investigated the
effect of a range of concentrations of the pan-PKC inhibitors
Ro31-8220 and Ro31-8425 on platelet activation by ADP. The
relative affinities of Ro31-8220 and Ro31-8425 for the classical
PKC isoforms have been reported (50, 51) and both are believed
to be pan-PKC inhibitors that do not discriminate between iso-
forms at the concentrations required to inhibit PKC in intact
cells.
Many pharmacological reagents have a reduced bioavailabil-
ity in plasma (31). Comparison of PAR-1-dependent responses
in PRP and washed platelets confirmed that Ro31-8220 had
reduced bioavailability in PRP in comparison with washed
FIGURE 6. Effect of Ro31-8220 on PKC-mediated phosphorylation and ADP-induced platelet aggregation. A, effect of Ro31-8220 on PKC substrate
phosphorylation in humanwashed platelets.Whole cell lysateswere resolved by SDS-PAGE and subjected toWestern blot analysis. Phosphorylation by PKC in
washed platelet lysates was detected using-phospho(Ser)-PKC substrate antibody, following activation by PMA (100 nM) (panel i) and ADP (100M) (panel ii)
in the presence of Ro31-8220 (Ro) (0.1, 0.3, 1, and 10M). Blots were stripped and reprobed for actin to determine equal loading. B, effect of PKC activation by
PMAondensegranule secretion fromhuman citratedPRP in response to stimulationbyADP.Human citratedPRPwasprepared and incubatedwith orwithout
increasing concentrations of PMA (nM), and dense granule secretion was monitored by ATP release, following stimulation by 100 M ADP. Panel i, represen-
tative trace. Panel ii, data are presented as mean S.E., n3. Platelets were incubated with DMSO, PMA (30 nM), or Ro31-8220 (10 M) for 3 min prior to ADP
stimulation. n 3. * indicates p 0.05 in comparison to DMSO-treated controls.
FIGURE 7. Potentiation of dense granule secretion by ADP in PKC null
mice. Mouse PRP from WT and PKC-deficient mice was prepared using
citrate as ananticoagulant and incubated in thepresenceor absenceof 10M
Ro31-8220 (Ro). Platelets were then stimulatedwith 100MADP. A, aggrega-
tion of WT and PKC null mice following activation by ADP monitored by
optical aggregometry. B, dense granule secretion monitored by ATP release
to 100MADP. Data are presented asmean S.E., n 3. * indicates p 0.05
in comparison with WT controls.
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platelets. A 100-fold higher concentration was required to
inhibit dense granule secretion in PRP, yet this concentration
was not sufficient to achieve the same level of inhibition of
aggregation as seen in washed platelets.
We have made the novel observation that submaximal
PKC inhibition causes a marked potentiation in the extent of
dense granule secretion and converts reversible to sustained
aggregation to a low concentration of ADP (3 M). At high
ADP concentrations, a partial blockade of PKC increases the
rate of onset of secretion, although this is followed by a
diminished overall secretory response, consistent with both
inhibitory and stimulatory actions of the PKC superfamily.
This potentiation effect was not seen downstream of PAR-1
receptor stimulation possibly because it initiates activation
through a Gq-dependent pathway. Consistent with this,
potentiation was also absent in platelets solely activated
through the P2Y1 ADP receptor, which also signals through
a Gq-dependent pathway. Our results suggest the PKC
superfamily has opposing regulatory roles in platelet activa-
tion downstream of ADP, an inhibitory role sensitive to low
concentrations of Ro31-8220 and an activatory role sensitive
to high concentrations. This is the first indication that pan-
PKC inhibitors can be used to selectively block one of these
opposing roles.
FIGURE 8. Effect of PKC inhibitor onaggregation, densegranule secretion, and levels of intracellular calciumof humanwashedplatelets andmouse
PRP in response to stimulation by ADP. A, effect of PKC inhibitor on aggregation and dense granule secretion in response to stimulation by ADP. Human
ADP-sensitive washed platelets were stimulated with 100M ADP in the presence and absence of varying concentrations of PKC inhibitor (0.3, 1, 10, and 30
M). Aggregation (panel i) and dense granule secretion (panel ii) were monitored as described previously. Panel iii, effect of PKC inhibitor on intracellular
calcium levels following ADP stimulation. Human washed platelets were loaded with Fura-2-AM and pretreated with or without varying concentrations of
PKC inhibitor before stimulationwith 100MADP. Fluorescencewasmeasuredbefore andafter (1min)ADPaddition, and the increase in intracellular calcium
concentration was calculated using the Grynkiewicz equation. B, mouse PRP from WT mice was prepared as described previously and incubated in the
presenceor absenceof 10or30MPKC inhibitor. Plateletswere then stimulatedwith100MADP.Panel i,aggregation followingactivationbyADPmonitored
by optical aggregometry. Panel ii, dense granule secretion monitored by ATP release induced by 100 M ADP. Platelets were incubated for 3 min with
inhibitor(s) or DMSO prior to ADP stimulation. Data are presented as mean S.E., representative traces shown, n 3. * indicates p 0.05 in comparison with
DMSO-treated controls.
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These results raise the question of why these broad spectrum
PKC inhibitors have differential and opposing effects at differ-
ent concentrations. It is possible that this is due to differential
sensitivities of the different PKC isoforms to Ro31-8220 and
Ro31-8425 or differential dose-response relationships for sub-
strate phosphorylation. It has been reported that PKC is one of
the most highly expressed novel isoforms of PKC in mouse
platelets even though it is absent in human platelets. In con-
trast, mice platelets express relatively low levels of PKC, which
is expressed at a high level in human platelets (18). Using PRP
from mice deficient in the novel isoforms, we have highlighted
a role for PKC in the potentiation. Treatment of PKC-defi-
cient mice with Ro31-8220 prior to ADP stimulation partially
reduced dense granule secretion demonstrating that the PKC
component that activates secretion is mediated by other PKC
isoforms. Because PKC is not expressed in human platelets,
potentiation must be mediated by another PKC isoform. We
therefore extended our study to the use of various PKC iso-
form-selective inhibitors that are currently available. The range
of concentrations of the inhibitors used included concentra-
tions thatwere lower than previously described in humanplate-
lets (15) in an attempt to ensure that observations made were a
result of isoform selectivity of the inhibitor rather than nonspe-
cific inhibition of the PKC superfamily. Treatment of human
washed platelets with the PKC inhibitor potentiated aggrega-
tion and dense granule secretion. This potentiation was also
observed following treatment with Go¨6983, which primarily
inhibits the classical isoforms PKC and PKC, further impli-
cating inhibition of PKC in the potentiation.
Treatment of platelets with indomethacin confirmed a criti-
cal role for TxA2 in the ability of ADP to stimulate sustained
aggregation and marked dense granule secretion in citrated
plasma. However, submaximal Ro31-8220 partially rescued
this, indicating that, although it may contribute, enhanced
TxA2 formation is not essential for potentiation. Use of inhibi-
tors of the two ADP G protein-coupled receptors, ARC that
inhibits P2Y12 and MRS that inhibits P2Y1, indicates that sig-
naling through P2Y12 but not P2Y1 is essential for the potenti-
ation, although this may be mediated through potentiation of
the synergy of the two receptors as the synergy is associated
with an increase in intracellular Ca2. Initially, it seems that
these results are at odds with previous reports that P2Y12
potentiates thrombin-induced calcium mobilization and that
inhibition of the P2Y12 receptor inhibits ADP-induced calcium
mobilization (54, 55). However, these observations refer to two
different mechanisms of calcium regulation. There is synergy
between P2Y12 and Gq-coupled receptors upstream of phos-
pholipase C activation, and therefore calcium responses are
increased as a result of increased inositol 1,4,5-trisphosphate
production. The PKC superfamily, however, has both inhibi-
tory and stimulatory effects on platelet Ca2mobilization. For
example, the novel isoform PKC negatively regulates intracel-
lular Ca2 following GPVI signaling (47). We observed an ele-
vation in intracellular Ca2 following treatment with both sub-
maximal andmaximal concentrations of Ro31-8220 supporting
published data that PKC suppresses agonist-induced Ca2 sig-
naling (31). This increase in Ca2 has been attributed to inhi-
bition of the plasma membrane Ca2-ATPase pump (56, 57),
which is inhibited by PKC, and this mechanism to increase
Ca2 potentially underlies the increase in platelet activation
observed here following submaximal PKC inhibition.
The inhibition of dense granule secretion by high Ro31-8220
has been reported downstream of multiple platelet agonists
suggesting a common target (21, 58).Multiple proteins, includ-
ing components of the soluble NSF attachment protein recep-
tors complex and the vesicular traffickingmachinery, which are
essential for secretion, are phosphorylated in a PKC-dependent
manner, including SNAP-23, syntaxin 4, and Munc18c (59–
63). Inhibition of one or more of these events may underlie the
positive role for PKC.
The data presented here identify both positive and negative
regulatory roles for the PKC superfamily in the regulation of
activation by ADP in human andmouse platelets. The data also
support previous reports that suggest differential regulatory
roles for the individual isoforms of PKC, indicating a role for the
classical isoform PKC in human platelets and PKC and the
novel isoform PKC in the regulation of ADP-induced platelet
activation inmouse platelets. This is the first report of an inhib-
itory role for a classical PKC isoform in platelets.
It is essential that powerful inhibitory pathways exist to pre-
vent unwanted platelet activation within the intact circulation.
ADP is a key feedback mediator in platelet activation and
thrombus formation. The release of low levels of ADP from
damaged cells is therefore potentially very dangerous as this
could give rise to unwanted thrombus formation. The work
described here demonstrates a previously unrecognized role for
members of the PKC superfamily in inhibiting platelet activa-
tion by low concentrations ofADPand therefore presents a new
pathway of prevention of unwanted platelet activation in
plasma. PKC activity is a key regulator ofmany signal transduc-
tion pathways in a variety of cell types, and it is therefore con-
sidered as a possible target for therapy for treatment of cancer
and various other diseases in addition to being a putative target
for antithrombotic therapies (64). The potentiation of platelet
aggregation downstream of low concentrations of ADP there-
fore has implications for the use of PKC-targeted antithrom-
botic and anti-cancer therapies.
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